alexa Abstract | The Efficacy of Malaria Chemoprophylaxis

Health Science Journal
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)


Introduction: Malaria is a highly contagious disease. According to W.H.O., its cases are expected to increase due to climate changes. Despite eradication efforts, malaria still remains one of the most significant causes of morbidity and mortality in tropical and subtropical regions. Many different antimalarial regimens are used; however resistance is emerging to many of them. Purpose: This critical review was conducted, in order to respond to the following questions. A) Which antimalarial regimen is the most effective? B) Which regimen is the safest for travelers in endemic regions? C) Which regimen is best tolerated? Methodology: The literature research was conducted through the Internet. The Medline and Cinahl databases were used, as well as the search engines google, altavista and lycos. The research included clinical trial articles. The studies were selected based on the aforementioned research questions and the chronological time limits. Results: Atovaquone/proguanil, tafenoquine, primaquine were the most effective regimens. Tafenoquine, as well as, primaquine were related to hemolytic incidents in individuals with G6PD deficiency, gastrointestinal disorders, backache and flu-like syndrome. Doxycycline and mefloquine were related to gastrointestinal and neurological disorders. Those were the less tolerated regimens. Conclusions: Atovaquone/proguanil, tafenoquine, primaquine were the most effective regimens. As far as safety is concerned, tafenoquine and primaquine should not be prescribed to individuals with G6PD deficiency. All the regimens were considered well tolerated, while most withdrawals due to adverse effects, took place in the doxycycline and mefloquine trials.

To read the full article Peer-reviewed Article PDF image

Author(s): Saridi Maria Pappa Vasiliki Saroglou George


malaria prophylaxis, malaria chemoprophylaxis, atovaquone - proguanil, tafenoquine, primaquine, doxycycline, mefloquinehe

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version